STOCK TITAN

enVVeno Medical (NVNO) details director stock option award of 135,883

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

enVVeno Medical Corp reported that director Francis Duhay received an award of 135,883 stock options on December 11, 2025. The options allow him to buy the company's common stock at an exercise price of $0.325 per share and expire on December 11, 2035.

The award was granted under the company's Amended and Restated 2016 Omnibus Incentive Plan and will vest in equal quarterly installments on the last day of each fiscal quarter during 2026. Following this grant, he beneficially owns 135,883 derivative securities directly.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Duhay Francis

(Last) (First) (Middle)
C/O ENVVENO MEDICAL CORPORATION,
70 DOPPLER

(Street)
IRVINE CA 92618

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
enVVeno Medical Corp [ NVNO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options $0.325 12/11/2025 A 135,883 (1) 12/11/2035 Common Stock 135,883 $0 135,883 D
Explanation of Responses:
1. The common stock options were issued to the Reporting Person on December 11, 2025 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
/s/ Francis Duhay 12/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did enVVeno Medical Corp (NVNO) report for December 11, 2025?

enVVeno Medical Corp reported that director Francis Duhay received an award of 135,883 stock options on December 11, 2025, as shown in the derivative securities table.

What are the key terms of Francis Duhay's stock option grant at enVVeno Medical (NVNO)?

The grant consists of 135,883 stock options to purchase common stock at an exercise price of $0.325 per share. The options expire on December 11, 2035 and were issued at a price of $0 for the derivative security itself.

When do the enVVeno Medical (NVNO) stock options granted to Francis Duhay vest?

According to the response footnote, the options are subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.

Under which plan were the 135,883 enVVeno Medical stock options granted?

The 135,883 stock options were issued under enVVeno Medical's Amended and Restated 2016 Omnibus Incentive Plan, as amended, which governs the company's equity incentive awards.

How many derivative securities does Francis Duhay beneficially own after this enVVeno Medical transaction?

Following this reported transaction, Francis Duhay beneficially owns 135,883 derivative securities directly, as indicated in the beneficial ownership column.

What is Francis Duhay's relationship to enVVeno Medical Corp (NVNO)?

The form identifies Francis Duhay as a director of enVVeno Medical Corp, with the director box checked and the filing made by one reporting person.

Envveno Medical Corporation

NASDAQ:NVNO

NVNO Rankings

NVNO Latest News

NVNO Latest SEC Filings

NVNO Stock Data

6.35M
16.28M
0.84%
29.88%
13.49%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
IRVINE